SHAAR ’s Post

Exciting Announcement! Mark your calendars for the Effective Statistician Conference 2024, taking place from February 13-15! Join us for an insightful session with Christine Fletcher as she presents "Statisticians Can Significantly Influence Drug Development - Do You Know How to Add Value?" Discover the pivotal role statisticians play in shaping the landscape of drug development! 🎉 Highlights of the speech include: ✅ Exploring the various ways statisticians can contribute to optimizing drug development processes. ✅ Unveiling strategies to effectively communicate statistical insights to stakeholders in the pharmaceutical industry. ✅ Case studies showcasing the tangible impact of statisticians on enhancing the efficacy and safety of pharmaceutical products. 📌 Ready to unlock the potential of statistical influence in drug development? Don't miss out on this enriching opportunity! Register now for the conference and gain access to invaluable knowledge, networking opportunities, and practical insights from industry experts! https://bit.ly/3upk4nK Secure your spot today at The Effective Statistician and be part of the statistical revolution in drug development! #TES2024 #DrugDevelopment #RegisterNow

An interesting session was held today at the #Biomed #Conference on "Is AI revolutionizing drug discovery and clinical development?". Dr. Eric A. Hughez, Global R&D and Chief Medical Officer of Teva Pharmaceuticals shared insights into the many opportunities and challenges of integrating AI into the pharmaceutical industry. He highlighted the transformative impact of AI and ML tools on drug discovery and development. He also proudly presented Teva's strategic collaboration at AION Labs. As many say today, AI is definitely a buzzword, but the need for change is urgent. As the current process for bringing a new drug to market takes around $2 billion, 10 years, and with approval chances below 90%, innovation is essential. We must leverage the immense capabilities, expertise, data, and resources of the pharma industry and combine them with cutting-edge technologies, to deliver faster, more accurate, personalized, and better value to patients worldwide. Mati Gill Yair Benita Sharon Kredo-Russo Arnon Fluksman Yael Spector

Session on "Breaking Boundaries with Innovations in Pharmaceutical"

Our latest report with Biofourmis analyses prevailing attitudes towards using digital measures in drug development. The pharmaceutical industry is bought in, but a lack of consensus on how and what to measure is creating a bottleneck. Greater industry collaboration will go a long way to help all of us usher in a new era of medicine. Download the full report and see what HealthXL community experts have to say ➡️ https://lnkd.in/egUvJkvC #pharma #digitalmeasures #drugdiscovery Jessie Bakker, MS PhD Digital Medicine Society (DiMe)

Arvato has already supported top companies in serialization. Now, we want to help #Pharmaceuticalcompanies# from other areas to simplify their tasks! #Logistics#: How could a #containermanagement# solution improve your value chain? (connected to your ERP) #Manufacture#: Could #TaskManagement# prioritize work on a paperless shop floor? (automatically) #Quality#: Can #AIsupport# you with error detection, inconsistency detection, data cleaning, and transformation? #Regulatory#: Next step in documentation: #Structured Component Authoring# (SCA) – What are the benefits? Our symposium will focus on how #AI and #DataManagement can put your pharmaceutical business to the next level. We will focus on Quality, Regulatory, Logistics, and Production. SAVE THE DATE!

🚀 Exciting Trends in Clinical Trials! 🌐 Is the surge in decentralized clinical trials fueled by fierce competition and innovative partnership models? Dive into the dynamic landscape of pharmaceutical R&D with our latest Frost Radar. With over 6,000 molecules in clinical development and 11,000+ in preclinical phases, the pharma industry is buzzing with activity. In Asia-Pacific (APAC), small to mid-sized pharma/biotech players are stepping up their game, rivaling Europe in clinical trial participation. Discover more about APAC's booming contract research organization (CRO) sector and how it's shaping the future of clinical research. Download a sample of our Frost Radar here: https://frost.ly/9pp #ClinicalTrials #PharmaR&D #DecentralizedTrials #HealthcareInnovation #Frost&Sullivan #IndustryTrends

AI can revolutionize pharmaceutical R&D, specifically the early stages of target selection and drug discovery. This contributes to medical innovation and optimized use of resources which will benefit patients and healthcare systems. A growing number of pharmaceutical assets based on AI platform use have entered into clinical trials over the past years. Once the overall slowdown (especially 2023) in biotech/pharma funding and thereby initiation of new clinical trials reverts back, we expect more and more such assets to enter phase I and to thereby further fill this pipeline. - More accurate drug target identification AI accelerates drug target identification by analyzing vast biological data, revealing potential targets faster and with greater precision than traditional methods - More efficient drug selection AI enhances efficiency by predicting drug-target interactions, prioritizing compounds with higher therapeutic potential, and reducing trial-and-error in pre-clinical and clinical stages - Innovation and public health gains Leveraging AI in drug discovery optimizes resources, expedites the development process, and fosters innovation, ultimately advancing precision medicine and improving patient outcomes Roland Berger Belgium happily supports local and international Health players to navigate their most critical challenges. Please feel free to contact our experts: Grégoire Tondreau Astrid Böhlke Maarten Rabijns Michael Baur #RolandBerger #RBHealthBelgium #Innovation #Healthcare #Pharma

🌟 Join Circuit Clinical for an enlightening webinar series on enhancing participant representation in research through community-based clinical trials! 💡 The first webinar in the series explores Circuit Clinical’s Community Research Network and the impact of community #healthcare on accelerating drug development and medical innovation. 🎤 Featured speakers will delve into: ➔ The significance of community-based research in the pharmaceutical landscape ➔ How community-based research sites differ from traditional models ➔ Challenges and considerations for pharmaceutical sponsors and CROs ➔ Factors to weigh when selecting a community research site 🔗 REGISTER HERE: https://buff.ly/3uP4XEq ⭐ Featured speakers: Alaina Anderson, MBA Elizabeth Seyfert Laura Warwick #DrugDevelopment #ClinicalResearch #PatientRecruitment #ClinicalSites #PatientParticipation

Exploring the Future of Medicine: AI and Regulatory Evaluation The European Medicines Agency (EMA) has taken a significant step forward in the integration of artificial intelligence (AI) within the pharmaceutical industry. In 2023, the EMA released a reflection paper that outlines the scientific principles essential for the regulatory evaluation of AI-assisted medicines. This paper not only highlights the potential of AI in transforming drug development but also emphasizes the importance of stakeholder engagement. The EMA has opened consultations to gather feedback from industry experts, running from July 19, 2023, to December 31, 2023. Additionally, the EMA co-organized a workshop focused on AI in medicine on November 20–21, 2023, fostering collaboration and discussion among key players in the field. As we navigate this evolving landscape, it's crucial for pharma professionals to stay informed and engage in these discussions to shape the future of medicine. 💡 What are your thoughts on the impact of AI! #Pharma #AI #RegulatoryAffairs #DrugDevelopment #EMA #Innovation

#Innovation has always been a big topic within the research industry, even more so now than ever, with the recent buzz around the potential of #ai and digitalisation in shaping the future of clinical research. If you're interested to learn more about current and future innovation within the #pharma sector, be sure to read Deloitte's latest report on "Measuring the return from pharmaceutical innovation" Furthermore, I am delighted to say that TrialHub has been prominently featured on ▪page 13▪, highlighting TrialHub’s pivotal role in revolutionizing clinical trial planning with our innovative data intelligence platform. Be sure to check out the full report LinkedIn in the comments below 👇 #TrialHub #ClinicalTrials #DigitalTransformation #InnovationInHealthcare #Biopharma #Deloitte #DeloitteReport #ClinicalResearch